High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial) Sahajal Dhooria, Shivani Chaudhary, Inderpaul Singh Sehgal, Ritesh Agarwal, Siddhant Arora, Mandeep Garg, Nidhi Prabhakar, Goverdhan Dutt Puri, Ashish Bhalla, Vikas Suri, Lakshmi Narayana Yaddanapudi, Valliappan Muthu, Kuruswamy Thurai Prasad, Ashutosh Nath Aggarwal
Source: Eur Respir J, 59 (2) 2102930; 10.1183/13993003.02930-2021 Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Sahajal Dhooria, Shivani Chaudhary, Inderpaul Singh Sehgal, Ritesh Agarwal, Siddhant Arora, Mandeep Garg, Nidhi Prabhakar, Goverdhan Dutt Puri, Ashish Bhalla, Vikas Suri, Lakshmi Narayana Yaddanapudi, Valliappan Muthu, Kuruswamy Thurai Prasad, Ashutosh Nath Aggarwal. High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial). Eur Respir J, 59 (2) 2102930; 10.1183/13993003.02930-2021
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021
Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial. Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018
A randomized, double-blind, placebo-controlled, phase III study of the safety and efficacy of interferon gamma-1b in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2007 - Clinical trial: new biological approaches to respiratory diseases Year: 2007
Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial Source: Eur Respir J, 56 (6) 2002808; 10.1183/13993003.02808-2020 Year: 2020
Effects of a concomitant therapy with Cineole (Eucalyptole) on exacerbation rate in COPD: A placebo-controlled double-blind trial Source: Annual Congress 2010 - COPD exacerbation Year: 2010
Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO) Source: ERJ Open Res, 8 (1) 00610-2021; 10.1183/23120541.00610-2021 Year: 2022
Efficacy of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomized controlled phase 3 trial Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018
Budesonide versus prednisone in acute wheezing: randomized double-blinded controlled placebo study Source: Annual Congress 2008 - Treatment and outcome of childhood asthma: new perspectives Year: 2008
Supplementation of N-acetylcysteine as an adjuvant in treatment of newly diagnosed pulmonary tuberculosis patients: A prospective, randomized double blind, placebo controlled study Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013
An investigator driven, single-centre randomised, double blind comparative study of standard vs high dose intravenous meropenem, in adult cystic fibrosis patients Source: Annual Congress 2010 - New aspects of cystic fibrosis Year: 2010
Efficacy of a short course of oral prednisolone for acute preschool viral-wheeze: a double-blind randomised placebo-controlled trial with stratification for systemic eosinophil priming Source: Eur Respir J 2003; 22: Suppl. 45, 388s Year: 2003
A prospective randomised double-blind placebo controlled trial of venlafaxine in patients with stable chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 32s Year: 2006
Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicentered open-label study Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008
Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19 Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19 Year: 2021
Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial Source: Eur Respir J, 54 (4) 1901030; 10.1183/13993003.01030-2019 Year: 2019
A randomised, placebo-controlled trial of inhaled mannitol in patients with bronchiectasis Source: Annual Congress 2008 - Infectious lung diseases including tuberculosis Year: 2008
“Stepping down” in mild-to-moderate asthmatic children being well controlled while receiving low doses of inhaled corticosteroids (ICS): Daily vs. cyclical ICS administration (prospective, randomized, multicentre, open-label trial) Source: Annual Congress 2013 –Asthma treatment and management in children Year: 2013
Open-label, randomized, comparative trial of the efficacy of levofloxacin versus clarithromycin SR therapy in complicated infectious exacerbation of COPD Source: Eur Respir J 2007; 30: Suppl. 51, 674s Year: 2007
A multicenter, randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the fluticasone/salmeterol (500/50 μg) combination administered with the new Elpenhaler inhalation device versus the innovative one in patients with asthma Source: Annual Congress 2009 - Quality of treatment in primary respiratory care Year: 2009